



## Program Agenda

DAY 1 THURSDAY – FEBRUARY 1, 2018		
2:00-2:10pm	Welcome and introduction	<b>Owen A. O'Connor</b>
2:10-2:15	Introduction of keynote presenter	TBD
2:15-3:00	Keynote address A journey through 3 decades of PTCL evolution: A clinicians' viewpoint on where we are going	<b>Christian Gisselbrecht</b>
SESSION 1: Epidemiology		
<b>Moderators:</b>	<b>Thomas Waldmann; WS Kim</b>	
3:05-3:20	Classification	<b>Pier Paolo Piccaluga</b>
3:25-3:40	Swedish Lymphoma Registry	<b>Thomas Relander</b>
3:45-4:00	Nasal NK relapsed after SMILE...What to do next	<b>HQ Huang</b>
4:05-4:20	Molecular classifiers of PTCL: Are TBX-21/GATA3 the ticket?	<b>Ryan Wilcox</b>
4:25-4:40	<b>BREAK</b>	
SESSION 2: Pathology		
<b>Moderators:</b>	<b>Pier Paolo Piccaluga; Sandeep Dave</b>	
4:45-5:00	Mouse models to study the pathogenesis of ALCL	Giorgio Inghirami
5:05-5:20	New technologies in identifying genetic signatures in T-cell	<b>Sandeep Dave</b>
5:25-5:40	Update on ALCL pathogenesis	<b>Andrew Feldman</b>
5:45-6:05	New insights into the molecular basis of T-cell lymphogenesis	David Weinstock
<b>6:05-9:00</b>	<b>Welcome Dinner</b>	
DAY 2 FRIDAY – FEBRUARY 2, 2018		
<b>7:00-8:00am</b>	<b>Breakfast Symposium</b>	
8:30-8:35	Day 2 opening remarks:	<b>Francine Foss</b>
SESSION 3: CTCL		
<b>Moderators:</b>	<b>Madeline Duvic; Nora Bennani</b>	
8:35-8:50	The evolving immunological milieu in CTCL	<b>Alain Rook</b>
8:55-9:10	Photopheresis- The next generation immunotherapy	Richard Edelson
9:15-9:30	The rare non-MF cutaneous lymphomas	Sean Whittaker
9:35-9:50	Molecular correlates in checkpoint inhibitor studies in CTCL	TBA
9:55-10:10	KIR antibody data in TCL	<b>Youn Kim</b>
10:15-10:30	<b>BREAK</b>	
SESSION 4: Molecular Pathways		
<b>Moderators:</b>	TBA and Giorgio Inghirami	
10:30-10:45	Emerging role of microenvironment in T-cell	<b>Nora Bennani</b>
10:50-11:05	Evolving therapies for the large granulocytic leukemias	<b>Thomas Loughran</b>
11:10-11:25	The role of RHOA mutations in T-cell lymphomas	<b>Sakata Yanagimoto</b>
11:30-11:45	Contemplating the role of JAK/STAT signaling in TCL	<b>Thomas Waldmann</b>
<b>12:30-1:30 pm</b>	<b>Lunch Symposium</b>	
2:00-2:15	Announcement of TCLLF Research Grant Sponsorship Winner	<b>Toni-Ann Lupinacci</b>



**SESSION 5: Case Presentations**

<b>Moderators:</b>	<b>Youn Kim; Francine Foss</b>		
2:20-2:45	Tumor stage and transformed MF	Fellow	<b>Foss</b>
2:45-3:10	LGL patients who failed methotrexate: What next?	Fellow	<b>Loughran</b>
3:10-3:35	Managing relapsed PTCL in non-transplant candidate	Fellow	<b>Chiattone</b>
3:35-4:00	Relapsed PTCL: Are there new agents to be considered?	Fellow	<b>Dearden</b>
4:05-4:20	<b>BREAK</b>		

**SESSION 6: Poster presentations**

<b>Moderators:</b>			
4:20-4:30	1.		
4:32-4:42	2.		
4:44-4:54	3.		
4:46-5:06	4.		
5:08-5:18	5.		
5:20-5:30	6.		
5:32-5:42	7.		
<b>5:42-7:42</b>	<b>Poster Walk Reception</b>		

**DAY 3 SATURDAY – FEBRUARY 3, 2018**

7:00-8:00am	Continental Breakfast		
8:10-8:15am	Day 3 opening remarks:		<b>Won Seog Kim</b>

**SESSION 7: Updates in Therapeutic Management**

<b>Moderators:</b>	<b>Owen O'Connor</b>		
8:15-8:30	Identifying the best bridge to transplant with new agents		<b>Ranjana Advani</b>
8:35-8:50	Transplant strategies in lymphomas		<b>Soon Thye Lim</b>
8:55-9:10	Emerging targets and opportunities for CAR-T in T-cell		<b>Andrei Shustov</b>
9:15-9:30	PD-1/PD-L1 as a target in NK T-cell: From biology to treatment		<b>YL Kwong</b>
9:35-9:50	What's on the horizon in new therapies in T-cell		<b>Ahmed Sawas</b>
9:55-10:10	Tailoring the molecular data to precision therapy		<b>Pier Luigi Zinzani</b>
10:15-10:30	What is the role for EZH2 inhibitors in T-cell Lymphoma		<b>Kunihiro Tsukasaki</b>
10:35-10:50	Immuno-oncology opportunities in T-cell		<b>Lorenz Trümper</b>
10:55-11:10	How I treat ATL		<b>Ali Bazarbachi</b>
<b>11:15-11:25</b>	<b>BREAK</b>		

**SESSION 8: Regulatory Insights: Moving the Field Forward**

<b>Moderators:</b>	<b>Francine Foss; Won Seog Kim; Owen O'Connor</b>		
11:25-11:40	What is the fastest route to regulatory approval in T-cell?		Angelo De Claro
11:45-12:00pm	Global T-cell Consortium		<b>WS Kim and PL Zinzani</b>
12:05-12:20	Case Match Control		<b>Owen O'Connor</b>
12:25-12:40	OPD in T-cell		TBA



<b>SESSION 9: Wrap-up Highlights</b>		
<b>Moderators: Francine Foss; Won Seog Kim; Owen O'Connor</b>		
12:45-12:55	Summary perspective on CTCL	<b>Madeleine Duvic</b>
12:55-1:05	Summary perspective on molecular pathogenesis	<b>Pier Paolo Piccaluga</b>
1:05-1:15	Summary perspective on evolving treatments for PTCL	Barbara Pro
1:15-1:25	Closing remarks	<b>Won Seog Kim</b>
1:25	Adjourn—Box lunch	